Public Notice, 36644 [05-12497]
Download as PDF
<![CDATA[
36644
Federal Register / Vol. 70, No. 121 / Friday, June 24, 2005 / Notices
The annualized cost to the public,
based on an average of 60 active grants
in the construction phase, is estimated
at: $576,818. There are no Capital Costs
to report. There are no operating or
Maintenance Costs to report.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies should
address one or more of the following
points: (1) Evaluate whether the
proposed collection of information and
recordkeeping are necessary for the
proper performance of the function of
the agency, including whether the
information will have practical utility;
(2) Evaluate the accuracy of the agency’s
estimate of the burden of the proposed
collection of information and
recordkeeping, including the
methodology and assumptions used; (3)
Enhance the quality, utility, and clarity
of the information to be collected and
the recordkeeping information to be
maintained; and (4) Minimize the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection and
recordkeeping techniques of other forms
of information technology.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the Office of
Regulatory Affairs, New Executive
Building, Room 10235, Washington, DC
20503, Attention Desk Officer for NIH.
To request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Jerry Moore, NIH
Regulations Officer, Office of
Management Assessment, Division of
Management Support, National
Institutes of Health, 6011 Executive
Boulevard, Room 601, MSC 7669,
Rockville, Maryland 20852; call 301–
496–4607 (this is not a toll-free number)
or e-mail your request to
jm40z@nih.gov.
Comments Due Date: Comments
regarding this information collection
and recordkeeping are best assured of
having full effect if received on or before
July 25, 2005.
Dated: June 17, 2005.
Jerry Moore,
Regulations Officer, National Institutes of
Health.
[FR Doc. 05–12596 Filed 6–23–05; 8:45 am]
BILLING CODE 4140–01–P
VerDate jul<14>2003
19:06 Jun 23, 2005
Jkt 205001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Public Notice
Centers for Disease Control and
Prevention (CDC), Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
SUMMARY: The Centers for Disease
Control and Prevention (CDC), National
Center for Infectious Disease (NCID),
Division of Bacterial and Mycotic
Diseases (DBMD) through its component
Branches has lead technical
responsibility for a number of Category
A, B and C bioterrorism agents and their
associated toxins (Bacillus anthracis,
Clostridium botulinum, Brucella sps.,
Burkholderia sps., Staphylococcus
entertoxin B, other food-or waterborne
bacterial pathogens, and other bacterial
agents). DBMD provides technical
support for the Nation’s prevention and
control efforts for human anthrax
disease. Since 2001, DBMD has been
collecting anthrax immune plasma from
Department of Defense volunteers who
received the licensed Anthrax Vaccine
Adsorbed (AVA) according to the
licensed schedule. DBMD has
contracted with industry to produce
anthrax immune globulin (AIG) from the
collected anthrax immune plasma using
anion-exchange chromatography. Since
2003, DBMD has been evaluating the
efficacy and pharmacokinetics of AIG in
small animals. Preliminary results of
these studies are now available, and are
being released to the public domain to
facilitate development of
immunotherapeutic agents for treatment
of human inhalational anthrax disease.
DBMD will continue to conduct AIG
studies in animals, and will release data
to the public as soon as the results
become available.
Persons or organizations who are
interested in receiving the preliminary
animal AIG study results, and in
receiving future updates, should contact
CDC and provide a mailing address.
CDC prefers to receive requests for
data electronically. These requests can
be e-mailed to the attention of Michael
J. Detmer at MDetmer@cdc.gov. Mailed
responses can be sent to the following
address: Michael J. Detmer, Division of
Bacterial and Mycotic Diseases,
National Center for Infectious Diseases,
Centers for Disease Control and
Prevention, 1600 Clifton Rd., NE., Mail
Stop C–09, Atlanta, GA 30333.
FOR FURTHER INFORMATION CONTACT:
Technical: Clare A. Dykewicz, M.D.,
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
M.P.H. Division of Bacterial and
Mycotic Diseases, National Center for
Infectious Diseases, Centers for Disease
Control and Prevention (CDC), 1600
Clifton Rd. NE., Mail Stop C 09, Atlanta,
GA 30333. Telephone (404) 639–4138,
e-mail: cad3@cdc.gov.
Dated: June 13, 2005.
James D. Seligman,
Associate Director for Program Services,
Centers for Disease Control and Prevention.
[FR Doc. 05–12497 Filed 6–23–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Alcohol Abuse and
Alcoholism; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title U.S.C.,
as amended. The grant applications and
the discussion could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel ZAA1 HH (40) SPECIAL
EMPHASIS PANEL REVIEW OF
FELLOWSHIP APPLICATIONS.
Date: August 2, 2005.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Lorraine Gunzerath, PhD,
MBA Scientific Review Administrator,
National Institute on Alcohol Abuse and
Alcoholism, Office of Extramural Activities,
Extramural Project Review Branch, 5635
Fishers Lane, Room 3043, Bethesda, MD
20892–9304, 301–443–2369,
lgunzera@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants,
National Institutes of Health, HHS)
E:\FR\FM\24JNN1.SGM
24JNN1
]]>Agencies
[Federal Register Volume 70, Number 121 (Friday, June 24, 2005)]
[Notices]
[Page 36644]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-12497]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Public Notice
AGENCY: Centers for Disease Control and Prevention (CDC), Health and
Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), National
Center for Infectious Disease (NCID), Division of Bacterial and Mycotic
Diseases (DBMD) through its component Branches has lead technical
responsibility for a number of Category A, B and C bioterrorism agents
and their associated toxins (Bacillus anthracis, Clostridium botulinum,
Brucella sps., Burkholderia sps., Staphylococcus entertoxin B, other
food-or waterborne bacterial pathogens, and other bacterial agents).
DBMD provides technical support for the Nation's prevention and control
efforts for human anthrax disease. Since 2001, DBMD has been collecting
anthrax immune plasma from Department of Defense volunteers who
received the licensed Anthrax Vaccine Adsorbed (AVA) according to the
licensed schedule. DBMD has contracted with industry to produce anthrax
immune globulin (AIG) from the collected anthrax immune plasma using
anion-exchange chromatography. Since 2003, DBMD has been evaluating the
efficacy and pharmacokinetics of AIG in small animals. Preliminary
results of these studies are now available, and are being released to
the public domain to facilitate development of immunotherapeutic agents
for treatment of human inhalational anthrax disease. DBMD will continue
to conduct AIG studies in animals, and will release data to the public
as soon as the results become available.
Persons or organizations who are interested in receiving the
preliminary animal AIG study results, and in receiving future updates,
should contact CDC and provide a mailing address.
CDC prefers to receive requests for data electronically. These
requests can be e-mailed to the attention of Michael J. Detmer at
MDetmer@cdc.gov. Mailed responses can be sent to the following address:
Michael J. Detmer, Division of Bacterial and Mycotic Diseases, National
Center for Infectious Diseases, Centers for Disease Control and
Prevention, 1600 Clifton Rd., NE., Mail Stop C-09, Atlanta, GA 30333.
FOR FURTHER INFORMATION CONTACT: Technical: Clare A. Dykewicz, M.D.,
M.P.H. Division of Bacterial and Mycotic Diseases, National Center for
Infectious Diseases, Centers for Disease Control and Prevention (CDC),
1600 Clifton Rd. NE., Mail Stop C 09, Atlanta, GA 30333. Telephone
(404) 639-4138, e-mail: cad3@cdc.gov.
Dated: June 13, 2005.
James D. Seligman,
Associate Director for Program Services, Centers for Disease Control
and Prevention.
[FR Doc. 05-12497 Filed 6-23-05; 8:45 am]
BILLING CODE 4163-18-P
